Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D
Shots:
- The company completes two P-III studies that compares proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic n subjects with type 1 (n=576) and type 2 diabetes mellitus (n=567) for 26wks.
- The focus of the study is to assess the equivalence in treatment-induced (TI) immunogenicity between GL-GLA and the reference biologic using pre-specified similarity margins while the secondary objectives were to assess the equivalence in efficacy and evaluate safety
- Both studies concluded there was equivalent TI immunogenicity with equivalent efficacy outcomes whereas safety endpoints were comparable between GL-GLA and the reference biologic
Ref: Gan & Lee | Image: WebsEdge
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com